Literature DB >> 6206846

Drug-binding properties of rat alpha 1-foetoprotein. Binding of warfarin, phenylbutazone, azapropazone, diazepam, digitoxin and cholic acid.

F Hervé, K Rajkowski, M T Martin, P Dessen, N Cittanova.   

Abstract

As part of an investigation into whether alpha 1-foetoprotein (alpha 1-FP) plays the same transport role in foetal serum as albumin does in the adult, the binding properties of both proteins were compared with respect to the binding of a series of compounds known to be bound by albumin's specific drug-binding sites. The binding of warfarin, phenylbutazone, azapropazone, diazepam, digitoxin and cholic acid by rat alpha 1-FP and serum albumin was studied by equilibrium dialysis at 4 degrees C. Rat alpha 1-FP was shown to have neither albumin's high-affinity site II (diazepam as marker) nor its site III (digitoxin and cholic acid as markers). High-affinity binding by alpha 1-FP was found for the specific markers (warfarin, phenylbutazone, azapropazone) of albumin's drug-binding site I. However, instead of albumin's one high-affinity site/molecule, a mean value of 0.5 site/molecule was obtained with rat alpha 1-FP. Charcoal treatment at neutral pH of rat serum albumin did not affect its measured binding properties, but treatment of the alpha 1-FP led to an increased affinity for warfarin, phenylbutazone and azapropazone without a change in the measured number of sites, indicating competition for binding at this site by (an) endogenous ligand(s). These results are discussed in terms of the structures of the two proteins and with respect to the physiological implications of the differences found.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206846      PMCID: PMC1144051          DOI: 10.1042/bj2210401

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  30 in total

1.  The interaction of ribonuclease with purine and pyrimidine phosphates. I. Binding of adenosine 5'-monophosphate to ribonuclease.

Authors:  Y P MYER; J A SCHELLMAN
Journal:  Biochim Biophys Acta       Date:  1962-03-05

2.  The binding sites on human serum albumin for some nonsteroidal antiinflammatory drugs.

Authors:  A Kober; I Sjöholm
Journal:  Mol Pharmacol       Date:  1980-11       Impact factor: 4.436

3.  Interaction between rat alpha 1 fetoprotein and fluorescent derivatives of estrone in relation to the position and type of the fluorescent label.

Authors:  B Desfosses; F Herve; M Moenner; P Urios; N Cittanova; P Dessen
Journal:  J Steroid Biochem       Date:  1983-12       Impact factor: 4.292

4.  Evidence for an intrinsic factor bound to rat alpha 1 fetoprotein. Fluorescence investigation.

Authors:  F Hervé; A M Grigorova; N Cittanova
Journal:  Reprod Nutr Dev       Date:  1981

5.  The binding of cholic acid and its taurine conjugate to serum proteins.

Authors:  C W Burke; B Lewis; D Panveliwalla; S Tabaqchali
Journal:  Clin Chim Acta       Date:  1971-04       Impact factor: 3.786

6.  Removal of fatty acids from serum albumin by charcoal treatment.

Authors:  R F Chen
Journal:  J Biol Chem       Date:  1967-01-25       Impact factor: 5.157

7.  On the interaction of diazepam with human, rat and mouse plasma proteins and erythrocytes.

Authors:  M Láznícek; J Lamka; J Kvĕtina
Journal:  Biochem Pharmacol       Date:  1982-04-01       Impact factor: 5.858

8.  Binding of digitoxin and some related cardenolides to human plasma proteins.

Authors:  D S Lukas; A G De Martino
Journal:  J Clin Invest       Date:  1969-06       Impact factor: 14.808

9.  Relations between high-affinity binding sites for L-tryptophan, diazepam, salicylate and Phenol Red on human serum albumin.

Authors:  U Kragh-Hansen
Journal:  Biochem J       Date:  1983-01-01       Impact factor: 3.857

10.  Primary structures of human alpha-fetoprotein and its mRNA.

Authors:  T Morinaga; M Sakai; T G Wegmann; T Tamaoki
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

View more
  7 in total

1.  Participation of the lone tryptophan residue of rat alpha-foetoprotein in its drug-binding sites. Comparison with rat serum albumin.

Authors:  F Hervé; M T Martin; K Rajkowski; P Dessen; N Cittanova
Journal:  Biochem J       Date:  1987-05-15       Impact factor: 3.857

Review 2.  Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding.

Authors:  F Hervé; S Urien; E Albengres; J C Duché; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

3.  Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling.

Authors:  Xiaomei I Liu; Jeremiah D Momper; Natella Y Rakhmanina; Dionna J Green; Gilbert J Burckart; Tim R Cressey; Mark Mirochnick; Brookie M Best; John N van den Anker; André Dallmann
Journal:  Clin Pharmacokinet       Date:  2020-11       Impact factor: 6.447

4.  Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein.

Authors:  F Herve; E Gomas; J C Duche; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

5.  Drug-binding properties of human alpha-foetoprotein.

Authors:  K Hirano; Y Watanabe; T Adachi; Y Ito; M Sugiura
Journal:  Biochem J       Date:  1985-10-01       Impact factor: 3.857

6.  Elucidation of the human serum albumin (HSA) binding site for the Cu-PTSM and Cu-ATSM radiopharmaceuticals.

Authors:  Nathan E Basken; Carla J Mathias; Mark A Green
Journal:  J Pharm Sci       Date:  2009-06       Impact factor: 3.534

7.  Drug-binding properties of rat alpha-foetoprotein. Specificities of the phenylbutazone-binding and warfarin-binding sites.

Authors:  F Hervé; K M Rajkowski; M T Martin; P Dessen; N Cittanova
Journal:  Biochem J       Date:  1986-10-15       Impact factor: 3.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.